Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two drugs, paromomycin and domperidone. Paromomycin is an aminoglycoside antibiotic primarily used to treat acute and chronic intestinal amebiasis (a parasitic infection of the intestines) and as adjunctive therapy for hepatic coma. It works by inhibiting protein synthesis in susceptible bacteria and parasites, leading to their death[1][2][3]. Domperidone is a dopamine receptor antagonist that acts as a peristaltic stimulant and antiemetic agent. It increases gastrointestinal motility, relieves symptoms such as nausea, vomiting, bloating, and discomfort due to delayed gastric emptying or gastroparesis[5][6][8]. The combination could theoretically be used when both antimicrobial action against intestinal pathogens (paromomycin) and prokinetic/antiemetic effects (domperidone) are desired.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paromomycin + domperidone.